Acurx Wins US Patent 12,534,470 for ACX-375C DNA Polymerase IIIC Inhibitors
On February 2, Acurx Pharmaceuticals secured US patent 12,534,470 covering compositions, methods of use and pharmaceutical formulations for its ACX-375C DNA polymerase IIIC inhibitor program. The company now holds four US patents plus grants in Israel, Japan, India and Australia, reinforcing its AI-supported antibiotic pipeline.
1. Patent Grant Details
On February 2, the US Patent and Trademark Office issued patent US 12,534,470, granting Acurx exclusive rights to compositions-of-matter, methods of use and pharmaceutical formulations for its ACX-375C DNA polymerase IIIC inhibitors.
2. Intellectual Property Expansion
This award brings Acurx's US patent count to four, complementing international grants in Israel, Japan, India and Australia with further applications pending to fortify its AI-driven antibiotic discovery platform.
3. Pipeline Progress and Preclinical Findings
Acurx's lead candidate ibezapolstat is Phase 3-ready for C. difficile, while novel preclinical inhibitors demonstrate microbiome selectivity and potential for oral and parenteral systemic absorption, targeting MRSA, pneumonia, bacteremia and anthrax.